A start-up called Ambrosia is charging $8,000 for blood transfusions from young people.
About 100 people have signed up to receive an infusion, according to founder Dr. Jesse Karmazin.
Anyone over age 35 can become an Ambrosia customer, said Karmazin, but most of the early adopters tend to be of retirement age. He also stressed that it's a range of people who have signed up.
The donated blood typically comes from teenagers, although anyone under age 25 is eligible. The company buys its supply from blood banks, which also sell blood to pharmaceutical companies. So high-schoolers donating their blood are not aware that it might be used on healthy adults.
Karmazin explained that the company does not claim that it can cure aging. Instead, he's hoping to recruit hundreds more people to research whether the transfusions can help fight particular symptoms associated with aging. Traditionally, biological aging hasn't been treated as a disease, which makes it challenging to study.
There is an 8.8 billion-dollar market for robotic laboratory automation systems, according to Kalorama Information. The healthcare research firm just completed a report on lab robots, and notes the imbalance between the high demand for diagnostics and the lack of supply of qualified technicians.
"More than two-thirds of clinical decisions are based on laboratory test results, and new tests are developed constantly," said Bruce Carlson, Publisher of Kalorama Information. "But a shrinking field of qualified laboratory personnel, while demand grows requires something to handle the tasks created."
Kalorama Information is a New York City-based market research firm that covers biotech, IVD and healthcare. The firm covered the market for lab robotics in its report Robotic Lab Automation. In the report, the firm notes that currently, many laboratories performing medical sample analyses still use manual distribution systems. The process starts first when the data for the incoming samples is captured. The samples are then placed in racks in batches, carried by employees to the various analysis stations and, if necessary, re-sorted from time to time for further analyses. Labor, notes Kalorama, is still about 60% of the cost of lab services.
Robotic technology can be harnessed to completely automate the work flow process. There are many laboratory processes suited for robotic automation – namely those processes that entail repetitive movements, such as pick and place; heating and cooling specimens; as well as mixing, shaking, and testing specimens. Essentially, laboratory robots manage specimen tubes, prepare them for testing, and allow for sample tracking throughout the testing process, from collection to results. The systems have various modules that participate in sample preparation, transport to analytical instruments — such as hematology, chemistry and immunoassay analyzers — and post-analytical storage. Each module often includes several units, such as decappers, sorters, centrifuges, analyzers, and refrigerators.
Read the full report.
Abionic SA, a developer of point-of-care diagnostic solutions, announced initial positive results from evaluation studies with its rapid PSP (pancreatic stone protein) test for sepsis risk assessment and management conducted at two internationally renowned university hospitals, Zurich University Hospital (Switzerland) and University College London Hospital (UK). Sepsis is the number one preventable death, if treated within the first hour. Abionic’s CE marked, abioSCOPE is the only device worldwide that provides results showing an indication of sepsis within 5 minutes.
"This POC test has the potential to help us identify sepsis patients more quickly than with currently available technologies. Introducing such a test complies with recently released NICE objectives as well as the guidelines issued earlier this year by the World Health Organisation (WHO)”
"Accurately diagnosing sepsis early is crucial so that appropriate treatment can be started. This provides the greatest chance of success and patient recovery. These initial clinical evaluation studies have demonstrated the potentially huge impact our five minute test can have in hospital ICUs and emergency departments," stated Dr. Fabien Rebeaud, Chief Scientific Officer of Abionic.
"Pancreatic stone protein (PSP) is currently one of the most promising biomarkers to identify sepsis patients early. A precise and accurate sepsis biomarker makes sense only if it is readily available to the clinicians, and as seen from the data generated in our recently completed study, the 5 minute abioSCOPE platform is unique to provide this service," said Professor Dr Rolf Graf, Head of Research, Department of Surgery and Transplantation, Zurich University Hospital.
Related article: Advances and pitfalls in using laboratory biomarkers for the diagnosis and management of sepsis